This study looks at how well a new drug called GB-0895 helps people with severe asthma that isn't controlled well by typical treatments like inhaled corticosteroids (ICS). Asthma is a condition where it's hard to breathe because the airways in the lungs are narrow or swollen. Participants in this study will either get the new drug or a placebo (a substance with no active drug) every six months for a year. A placebo is used to see if the real medicine works better than no treatment.

The study takes place over several phases and will last up to about 2.5 years, with visits every 1-2 months after the first month. An optional extension period is available for those who want to keep taking GB-0895. Up to 786 participants aged 12 to 80 will be involved, and their safety and health will be monitored closely throughout the study. Participants must have been diagnosed with asthma for at least two years and must have had recent asthma problems despite using standard treatments.

• Length: Study lasts about 2.5 years with visits every 1-2 months.
• Treatment: Randomly receive GB-0895 or placebo every 6 months.
• Eligibility: Ages 12-80 with severe asthma uncontrolled by standard treatments.